In women undergoing IVF, no triptorelin-treated patient had a premature LH surge, compared with 23% receiving placebo.
In plain wordsIn women undergoing IVF, premature LH surges occurred in no triptorelin-treated patients versus 23% receiving placebo.
- Outcome
- DecreasePremature LH surge
- Study
n = 240
- Comparator
- Placebo
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 15, 50 or 100 microg dailyAs given in this study (human).
Measurements
- Premature LH surge
- 23%
- placebo
Source sentences
A premature LH surge occurred in 23% of placebo-treated patients, but in none of the triptorelin acetate-treated patients.
3 context sentences(design, population, supporting numbers)
Thus, we performed a prospective, randomized, double-blind, placebo-controlled study to determine the minimal daily dose of triptorelin acetate needed to suppress a premature LH surge during IVF treatment in a long protocol.
A total of 240 women (60 in each group) was randomized to either placebo or to one of three doses of triptorelin, i.e. 15, 50 or 100 microg daily.
Ovarian stimulation was performed with two or three ampoules of FSH daily.